UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported)
                                 March 6, 2008

                           HEMISPHERX BIOPHARMA, INC.
             (Exact name of registrant as specified in its charter)

                           Delaware 0-27072 52-0845822
               (state or other juris- (Commission (I.R.S. Employer
           diction of incorporation) File Number) (Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania 19103
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080


          (Former name or former address, if changed since last report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     [ ] Written  communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     [ ] Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     [ ]  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     [ ]  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))








Section 8 - Other Events

Item 8.01 Other Events.


Following our  submission  of a clarifying  amendment on January 9, 2008, to our
NDA  application  and a subsequent  face-to-face  meeting  with the Agency,  the
number of items  necessary to accomplish a complete NDA for filing  purposes has
been reduced from an original fourteen (14) to five (5).  Specifically,  for NDA
filing purposes,  9/14 of the original  incomplete items noted in the FDA letter
received December 5, 2007 are no longer considered filing - related issues.  The
remaining  open items are being  promptly  addressed by us thru a series of five
(5) additional Amendments to the NDA.

For more information, please see the March 6, 2008 press release attached hereti
as exhibit 99.1

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d)      Exhibits

The following Exhibit is filed as part of this report:

Exhibit No.                Description

Exhibit 99.1               Press Release dated March 6, 2008


                                         SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                   HEMISPHERX BIOPHARMA, INC.


March 10,  2008               By:  /s/ William A. Carter
                                   --------------------------
                                   William A. Carter M.D.,
                                   Chief Executive Officer







                                                               Exhibit 99.1


Company/Investor Contact:
Dianne Will                                          Sean Collins, Sr. Partner
Hemispherx Biopharma, Inc.                           CCG Investor Relations
518-398-6222                                         310-477-9800
ir@hemispherx.net


  HEMISPHERX BIOPHARMA REACHES AGREEMENT WITH FDA ON SPECIFIC STEPS TO ACHIEVE
                     COMPLETE NDA ON PROPOSED CFS TREATMENT

                       ... No Additional Studies Indicated

Philadelphia,  PA,  March  6,  2008---Hemispherx  Biopharma,  Inc.  (AMEX,  HEB)
announced  today that,  following its  submission  of a clarifying  amendment on
January 9, 2008, to its NDA  application and a subsequent  face-to-face  meeting
with the Agency,  the number of items necessary to accomplish a complete NDA for
filing  purposes has been reduced  from an original  fourteen  (14) to five (5).
Specifically,  for NDA filing  purposes,  9/14 of the original  incomplete items
noted in FDA letter received  December 5, 2007 are no longer considered filing -
related  issues.  The remaining open items are being  promptly  addressed by the
Company thru a series of five (5) additional  Amendments to its NDA as described
below.

Specifically, the open items-requisite for a complete NDA filing status - may be
grouped into one of two  categories:  Category (1)  Administrative  items (four)
include:  (a) transfers of additional  clinical  records (termed  "CRF's"),  (b)
transfer of several  documents  previously  submitted to the FDA, (c) additional
clinical data reconciliations (compiled from the CRF records) and (d) additional
computer generated charts which summarize  specific parts of the CRFs.  Transfer
of  these  records  will  thereby   allow  the  Agency   reviewers  to  evaluate
independently  the  statistical  efficacy  /safety  conclusions of the Company's
existing NDA.  Category (2) (One item): a reformatting and enlarged  analysis of
the existing  pharmacokinetics  ("PK") report to more closely align with current
International Committee on Harmonization ("ICH") guidelines.

Importantly,  the company  believes no further studies are required to achieve a
complete  NDA filing  status for  purposes  of  regulatory  review of the entire
document.

As part of the agreement reached with the Agency, the additional  files/data may
be  submitted  sequentially  as separate NDA  Amendments  to the existing NDA to
accelerate  the review  process.  Submission  of these  Amendments to the FDA is
expected to begin this week with all  Amendments  expected to be  completed  and
filed shortly. A collaboration with Octagon Research Solutions, a major provider
of electronic  filings of regulatory  documents,  will facilitate and accelerate
the overall filing process.  These  Amendments will add to the overall data base
of  the  existing   NDA   (submitted   October  10,  2007)  and  the   company's
pre-submission of non-clinical  information (submitted December 29, 2006), which
was assigned the original NDA number.

While the company is optimistic as to the progress of the NDA filing,  there are
no  assurances  that the FDA will  accept the  amended  NDA for  review,  and if
accepted there are no assurances that the NDA will be approved.



About CFS and Ampligen(R)(poly I: Poly C12U), an Experimental Therapeutic
A recent independent study enumerated three primary causes of early death in CFS
populations  at  large  (without  administration  of  Ampligen(R))  that  may be
attributable  to the  disease:  1)  cardiovascular  events,  2)  suicide  and 3)
untreatable  life-threatening  malignancies/tumors.  Within the NDA,  Hemispherx
addresses how Ampligen(R),  an experimental  therapeutic,  may address these and
other high risk aspects of CFS.

Over its developmental  history,  the experimental  therapeutic  Ampligen(R) has
received various designations,  including Orphan Drug Product Designation (FDA),
Emergency   (compassionate)   Cost  Recovery  Sales   Authorization   (FDA)  and
"promising"  designation by the Agency on Health Research  Quality (AHRQ).  Four
well  controlled,  or pivotal,  trials are now being  reported in their entirety
within  Hemispherx  Biopharma's  NDA  submission,  which  covers more than 1,200
subjects evaluated with more than 90,000 dose administrations.  The experimental
therapeutic  was  originally  discovered  and  developed  at The  Johns  Hopkins
University and thereafter licensed to Hemispherx.

Chronic  Fatigue  Syndrome  (CFS) has a top  priority  status at the Centers for
Disease Control and Prevention ("CDC"),  the governmental agency responsible for
disease  surveillance,  as a serious and  debilitating  disease in the U.S.  The
disorder  reflects a major unmet medical  need.  There are currently no approved
therapies for CFS. The Agency for Research and Quality,  a health service arm of
the U.S. Department of Health and Human Services,  reported that Ampligen(R), an
experimental  therapeutic,  yielded the most promising  clinical results to date
related to CFS. Only regulatory  agencies can determine whether any experimental
therapeutic,  including Poly I: Poly C12U (Ampligen(R)) is "safe and effective."
At this time,  Ampligen(R),  an experimental  therapeutic,  is only available in
specific   clinical  trial  settings   conducted  under  specific   governmental
authorizations.  It has not been  determined  to be "safe and  effective" by any
governmental  body.  Ampligen(R)  represents  an entirely new class of RNA-based
drug therapies.  The Company's prompt response to the questions posed by the FDA
was made possible by the  broad-based  team of clinical and  scientific  experts
assembled during 2007, with experience in successful global  development of NDAs
for new molecular entities ("NMEs"), such as Ampligen(R).

About Hemispherx Biopharma
Hemispherx Biopharma,  Inc. is an advanced  biopharmaceutical company engaged in
the manufacture  and clinical  development of new drug entities for treatment of
seriously debilitating disorders. Hemispherx's flagship products include Alferon
N Injection(R)  (FDA approved for a category of sexually  transmitted  diseases)
and the experimental  therapeutics  Ampligen(R) and Oragens(R).  Ampligen(R) and
Oragens(R) represent experimental RNA nucleic acids being developed for globally
important debilitating diseases and disorders of the immune system. Hemispherx's
platform  technology  includes  large and small agent  components  for potential
treatment  of  various  severely  debilitating  and life  threatening  diseases.
Hemispherx has in excess of 90 patents comprising its core intellectual property
estate and a fully commercialized product (Alferon N Injection(R)).  The Company
wholly owns and exclusively operates a GMP certified  manufacturing  facility in
the United States for commercial  products.  For more  information  please visit
www.hemispherx.net



Contact:
Hemispherx Biopharma, Inc.
Dianne Will, Investor Relations
(518) 398-6222, Fax: (618) 398-6369

HEB's Web Site: www.hemispherx.net

Information  contained in this news release other than  historical  information,
should be considered  forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition,  changing market conditions, change in laws and regulations
affecting these industries and numerous other factors  discussed in this release
and in the Company's  filings with the Securities and Exchange  Commission.  Any
specifically referenced investigational drugs and associated technologies of the
Company  (including  Ampligen(R),  Alferon LDO and Oragens) are  experimental in
nature  and as such  are not  designated  safe  and  effective  by a  regulatory
authority for general use and are legally available only through clinical trials
with the referenced  disorders.  The  forward-looking  statements  represent the
Company's  judgment  as of the  date of this  release.  The  Company  disclaims,
however,  any intent or obligation to update these  forward-looking  statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(R) do not imply that the product will ever be specifically  approved
commercially for these other treatment indications; Similarly, the completion of
NDA filing process with Ampligen(R) does not imply that the product will ever be
approved commercially.